secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001193125-25-246964
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix raises $250M in registered offering; shares priced at $10.21
------------------------------------------------------------------

- Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.
- Proceeds to fund clinical development of bexobrutideg in CLL and autoimmune indications.
- New and existing investors participate, including General Atlantic, Redmile, Braidwell, Deep Track, Perceptive Advisors.
- Offering expected to close October 23, 2025, subject to customary conditions.
- J.P. Morgan, Jefferies, Stifel act as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312525246964/0001193125-25-246964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312525246964/d46133d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-246964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer